A Randomized, Double-Blind, Placebo-Controlled, Ascending Oral Single Dose Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAK-418 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 30 May 2018
At a glance
- Drugs TAK 418 (Primary)
- Indications Inborn genetic disorders
- Focus Adverse reactions
- Sponsors Takeda
- 22 May 2018 Status changed from active, no longer recruiting to completed.
- 06 Feb 2018 Status changed from recruiting to active, no longer recruiting.
- 01 Aug 2017 New trial record